Totect FDA Approval History
FDA Approved: Yes (First approved September 6, 2007)
Brand name: Totect
Generic name: dexrazoxane
Company: TopoTarget A/S
Treatment for: Anthracycline Extravasation
Totect (dexrazoxane) is a topoisomerase inhibitor used as a detoxifying agent for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.
Development timeline for Totect
| Date | Article |
|---|---|
| Sep 7, 2007 | Approval Totect Approved in the United States |
| May 31, 2007 | TopoTarget elaborates on the specific initiatives to obtain FDA approval of Totect |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
